Actos Lawsuit Help

Actos Lawsuit Update

Actos lawsuits have been filed by plaintiffs and the cases have begun to be litigated. More Actos lawsuits continue to be filed across the country.

In California, a jury awarded Jack Cooper and his wife $6.5 million for their Actos lawsuit.

Other Actos lawsuits have been filed with a Multidistrict litigation (MDL) pending in Louisiana. Several class action suits have been filed in California and Illinois as well.

Takeda Pharmaceuticals Sued in the Actos Lawsuit

Takeda Pharmaceuticals is responsible for the manufacture and sale of Actos, a drug that is used to manage the type 2 diabetes conditions. The company is being sued for damages because its drug, Actos, has been confirmed to be defective because it leads to bladder cancer after sustained use in patients. Another serious side effect of Actos is that it causes congestive heart failure.

Actos is also known medically as Pioglitazone. The drug is still being sold freely without restrictions despite the serious risks it poses to its users. Takeda Pharmaceuticals is yet to recall the drug. The Irony of this situation is that the evidence linking Actos to bladder cancer was initially pointed out subtly by Takeda Pharmaceuticals but they still continue to market Actos aggressively. They insist on selling while conducting further research on these life-threatening side effects.

Takeda Pharmaceuticals chose to change the label on Actos drugs while the drug regulators in other countries such as Germany and France chose to ban the sale of Actos entirely. This is because people that have taken Actos for over a year have a forty percent chance of developing cancer of the bladder.

History of the Drug behind the Actos Lawsuit

Actos was first introduced onto the market in 1999 by Takeda Inc. It is very effective in managing type 2 diabetes but with serious side effects. Unfortunately, the public was never informed of these serious risks associated with the use of Actos drug. It is the responsibility of prescription drug manufacturers to inform the public of any serious risks and adverse side effects associated with any drug they sell. The manufacturers are also required to carry out tests in order to ensure that their products are safe for managing various health conditions.

In 1999, Takeda had test results of studies in laboratory animals that showed there was a strong link between Actos and bladder cancer. Unfortunately, the manufacturing company kept these results from health regulators and went on to launch their drug onto the market.

In 2002, Takeda released promotional material for Actos for a trade show involving pharmaceutical industries. The promotional material was misleading as it emphasized undemonstrated results and omitted important information regarding the safety of Actos. By so doing, the Federal Food, Drug and Cosmetic Act was violated. The department of Human and Health Services Division of Drug Marketing, Advertising and Communications (DDMAC) issued a letter to Takeda concerning their act of violation.

Soon after the drug was approved to be released onto the market by the FDA, the company had also been directed to undertake a study on the safety and effectiveness of Actos by the same approval body. Until 2003, Takeda had yet to carry out any follow ups on their drug’s efficacy and safety. In 2003, the company craftily undertook a study that would go on to become a ten year trial for Actos. This study design denies the public final access to results until after the patent for Actos expires.

Takeda also hastily denied the link between Actos and bladder cancer in another study carried out in May 2005. However, in 2011, the company released interim results that showed an increased risk in bladder cancer among users of Actos in their ten year trial study.

Studies Supporting the Actos Side Effects

In 2005, a published report on a study of Takeda’s drug, Actos showed that the patients managing diabetes type 2 with Actos had 14 bladder cancer cases against five in the group with patients on a different medication.

A review of the link between bladder cancer and Actos was carried out by the FDA in 2011. This was after an announcement by the regulating body in June 2011 that it was reviewing the diabetes drug for increased risks of bladder cancer. The study was based on a safety review in September 2010.

Another study was undertaken in May 2011. It reviewed reports sent to the FDA between 2004 and 2009. The results showed that out of half a million side effects reports involving different medications, a fifth of them clearly showed a link between bladder cancer and the Actos drug.

Charges and Counts Made by Actos Plaintiffs

The Actos lawsuit holds the defendant accountable for failing to warn the public of the risks posed by Actos drug use after 12 months. Associated risks include bladder cancer and heart failure. The company is being held accountable for the manufacture of a defective drug which is still being sold despite the serious side effects it poses to the populace.

Plaintiffs also claim that Actos was not properly tested to ascertain the seriousness of its side effects and hence Takeda Pharmaceuticals provided misleading data to the public on the effectiveness of Actos. Takeda is also being blamed for putting its financial interests first and ignoring consumer safety. This is also strongly indicated by the company’s continued sales of the drug despite several Actos lawsuits being filed in various states.

If you developed bladder cancer because you used Actos to manage your diabetes type 2, you may be eligible for compensation.

Actos Bladder Cancer News

Find out if you qualify for an Actos Bladder Cancer Lawsuit!

Actos Bladder CancerOn June 15th, 2011, the FDA announced that use of Actos for more than one year may be associated with an increased risk of bladder cancer.  Actos or Pioglitazone (HCI) is a drug manufactured by Takeda Pharmaceuticals and was marketed for use with treating adults with Type 2 Diabetes. This information is drawn upon from the FDA’s five-year interim analysis and their ongoing ten-year epidemiological study.

The five-year study showed that despite there being no overall increased risk of bladder cancer in patients that use Actos, there is still an increased risk of bladder cancer in patients that use Actos over long periods of time and also in those exposed to the highest doses of Actos. The FDA is aware of a recent epidemiological study of Actos in France which shows an increased risk of Actos bladder cancer in patients who were prescribed the drug.

Based on this study, France has suspended the use of Actos and Germany has recommended not to prescribe Actos to new patients.

If you have taken Actos you may be entitled to an Actos Bladder Cancer Lawsuit.

Actos Bladder Cancer Research

Studies are noted in medical journals like the British Medical Journal and the New England Journal of Medicine that explain the risks of taking Actos and the chances of developing Actos bladder cancer when taking Actos for more than one year.

The New England Journal of Medicine’s website, Journal Watch, reported that researchers had identified 116,000 patients with type 2 diabetes that were new users of oral antidiabetic drugs and that after a follow-up of less than 5 years, 470 patients were diagnoses with Actos bladder cancer.

Patients who used Actos were associated with having 83% higher risk of developing bladder cancer, a dramatic increase than those compared with patients who had never taken Actos. The rate of bladder cancer increased significantly with:

  • Length of Actos use
  • The highest rates in patients who were exposed for less than 2 years
  • In patients whose collective, long term dosage exceeded 28,000mg.

Additionally, websites such as, trusted online medical source WebMD and even on the American Diabetes Association website all discuss the risks, side effects and the increased risk of Actos bladder cancer with patients. With all the information available to the public, Actos Bladder Cancer Lawsuit are increasing and

According to a recent study reported on WebMD, researchers analyzed over 115,000 patients between 1988 and 2009 who have taken Actos for more than two years were determined to have double the risk of developing Actos bladder cancer when compared to patients who have never taken Actos. According to WebMD, a spokesperson for Takeda Pharmaceuticals in Deerfield, Ill., did supply the following statement:

“Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes more than 12 years of clinical and patient experience with the product.”

“As a company, Takeda is committed to ongoing clinical research to understand and investigate potential safety concerns, and is currently supporting several ongoing studies, including a 10-year epidemiological study, investigating the potential relationship between Actos and bladder cancer.”

Seeking Help with your Actos Bladder Cancer Lawsuit

Maximize your possible claim in an Actos Bladder Cancer Lawsuit today by contacting our lawyers to find out if you may qualify.